February 22, 2015 / 9:54 PM / in 3 years

Valeant to acquire Salix in $14.5 bln deal

NEW YORK, Feb 22 (Reuters) - Valeant Pharmaceuticals International Inc. agreed to acquire Salix Pharmaceuticals Ltd. for $158.00 per share, or a total enterprise value of $14.5 billion, the two companies said on Sunday.

The transaction, an all-cash tender offer for all the outstanding shares of Salix, was approved by the boards of directors of both companies, the companies said in a news release.

The merger is expected to yield more than $500 million in annual cost savings from the cost base of the combined company, the release said. (Reporting by Herbert Lash; Editing by Frances Kerry)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below